55115-99-6

Basic information

• Product Name: 1-Benzyl-cis-3,5-dimethylpiperazine
• Synonyms: 1-Benzyl-cis-3,5-dimethylpiperazine;cis-1-Benzyl-3,5-diMethylpiperazine;cis-4-Benzyl-2,6-diMethylpiperazine));Piperazine, 3,5-diMethyl-1-(phenylMethyl)-, (3R,5S)-rel- (or Piperazine, 3,5-diMethyl-1-(phenylMethyl)-, cis-;(3R,5S)-1-Benzyl-3,5-dimethylpiperazine
• CAS NO: 55115-99-6
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.3113
• Mol File: 55115-99-6.mol
• Article Data: 2

Chemical Properties

• Melting Point: 48-50 °C
• Boiling Point: 291.5°C at 760 mmHg
• Flash Point: 109.5°C
• Appearance: /
• Density: 0.964g/cm³
• Vapor Pressure: 0.00194mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.38±0.60(Predicted)
• CAS DataBase Reference: 1-Benzyl-cis-3,5-dimethylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-cis-3,5-dimethylpiperazine(55115-99-6)
• EPA Substance Registry System: 1-Benzyl-cis-3,5-dimethylpiperazine(55115-99-6)

Safety Data

• Hazardous Substances Data: 55115-99-6(Hazardous Substances Data)

Usage

Description

1-Benzyl-cis-3,5-dimethylpiperazine is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which includes a benzyl group attached to a piperazine ring with methyl groups at the 3 and 5 positions. 1-Benzyl-cis-3,5-dimethylpiperazine plays a significant role in the development of potent agonists for the CB1 cannabinoid receptor.

Uses

Used in Pharmaceutical Industry:
1-Benzyl-cis-3,5-dimethylpiperazine is used as a key intermediate for the preparation of tricyclic indole-3-carboxamides. These compounds are structurally restricted analogs of bicyclic indoles and have been found to act as potent CB1 cannabinoid receptor agonists. The activation of CB1 receptors has been associated with various therapeutic effects, including pain relief, appetite stimulation, and neuroprotection.
As a result, 1-Benzyl-cis-3,5-dimethylpiperazine plays a vital role in the development of new drugs targeting the CB1 receptor, which can potentially be used to treat a range of conditions such as chronic pain, multiple sclerosis, and neurodegenerative diseases.

InChI:InChI=1/C13H20N2/c1-11-8-15(9-12(2)14-11)10-13-6-4-3-5-7-13/h3-7,11-12,14H,8-10H2,1-2H3/t11-,12+

Upstream product

• 100-39-0 benzyl bromide 
• 21655-48-1 cis-2,6-dimethylpiperazine 

Downstream Products

• 300553-64-4 1R-[4-(4-benzyl-2R,6S-dimethyl-piperazin-1-yl)pyrimidin-2-yl]ethyl butyrate 
• 300553-65-5 Butyric acid (S)-1-[4-((2S,6R)-4-benzyl-2,6-dimethyl-piperazin-1-yl)-pyrimidin-2-yl]-ethyl ester 
• 958030-49-4 rel-6-(((2R,6S)-4-benzyl-2,6-dimethyl-1-piperazinyl)carbonyl)-13-cyclohexyl-N-((dimethylamino)sulfonyl)-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide 
• 347196-36-5 cis-1-(3-Cyanobenzenesulphonyl)-2,6-dimethyl-4-phenylmethylpiperazine 
• 856765-57-6 C₃₀H₃₇N₃O₂ 

Relevant articles and documents

NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.